Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
WM Technology, Inc. Q4 2025 Earnings Call - Cash build and discipline cushion revenue pressure
Weedmaps closed 2025 with a tale of two realities. Top line weakened as industry headwinds—pricing compression, illicit market competition, and heavy excise taxes—dented spend from core clients, drivi...
- Q4 2025 revenue was $43 million, down approximately 10% year‑over‑year.
- Full year 2025 revenue was $175 million, a decline of about 5% versus 2024.
- Adjusted EBITDA for 2025 was $40 million, modestly below 2024’s $43 million.
- +12 more takeaways
PagerDuty, Inc. Q4 FY2026 Earnings Call - AI Operations and Flex Pricing Fuel Enterprise Wins as ARR Stabilizes
PagerDuty closed FY2026 with stabilized ARR near $499 million, expanding margins and a bold repositioning toward AI operations and consumption-based pricing. Q4 delivered $125 million in revenue, 24% ...
- Revenue $125 million in Q4, up 3% year-over-year, with FY2026 revenue nearly $493 million, up 5% YoY.
- Total ARR exited Q4 at approximately $499 million, effectively flat year-over-year, signaling stabilization rather than re-acceleration.
- PagerDuty reported its first full year of GAAP profitability; Q4 GAAP net income was $11 million and FY GAAP net income was $174 million, the latter including a one-time $169 million tax benefit from release of a valuation allowance.
- +14 more takeaways
Afya Q4 2025 Earnings Call - Record cash and margins, but 2026 guidance flags margin compression as company invests to build a physician ecosystem
Afya closed 2025 with headline numbers that read like a strategy checkmark. Revenue reached BRL 3.697 billion, adjusted EBITDA hit BRL 1.68 billion and margins expanded to 45.4%, while operating cash ...
- 2025 revenue was BRL 3,697 million, up 12% year-over-year, in line with midpoint guidance.
- Adjusted EBITDA for the twelve months reached BRL 1,680 million, up 15% year-over-year, producing a record adjusted EBITDA margin of 45.4% (up 130 bps).
- Operating cash flow was BRL 1,548 million for the year, a 6% increase, with operating cash conversion of 93.7%.
- +15 more takeaways
American Public Education Inc. 4Q 2025 Earnings Call - Revenue and Margins Improved Despite APUS TA Freeze, Institutional Combination and Campus Expansion Set 2026 Up
APEI closed 2025 with a clear message, not bravado. The company grew consolidated revenue and expanded adjusted EBITDA despite a 43-day federal TA registration interruption at APUS that shaved roughly...
- Consolidated 2025 revenue was $648.9 million, up 3.9% year over year, and would be roughly 7% growth on an apples to apples basis excluding Graduate School USA.
- Full year adjusted EBITDA rose to $85.7 million, up 18.6% from 2024, and adjusted EBITDA margin expanded 164 basis points to 13.2%.
- APUS faced a 43‑day federal government shutdown interruption that depressed Q4 TA registrations, driving APUS Q4 revenue down 13.8% to $71.0 million and net course registrations down 15.3% to 82,200.
- +15 more takeaways
EverCommerce Q4 2025 Earnings Call - AI-First Push and ZyraTalk Drive Product Momentum
EverCommerce closed 2025 with steady top-line growth, expanded margins, and a clear strategic pivot to AI-first productization. Q4 revenue of $151.2 million beat guidance, adjusted EBITDA held at $44....
- Q4 2025 revenue was $151.2 million, up 5.2% year over year, beating the midpoint of guidance.
- Q4 adjusted EBITDA was $44.2 million, flat year over year, yielding a 29.2% adjusted EBITDA margin.
- Adjusted gross profit for Q4 was $117.0 million, with an adjusted gross margin of 77.5%.
- +17 more takeaways
Ascend Wellness Holdings Q4 2025 Earnings Call - Densification and cost cuts hold margins amid relentless price compression
Ascend closed 2025 with a playbook that reads like damage control and discipline. Revenue fell to $500.6 million for the year, but management leaned into densification, verticalization, and a $30 mill...
- Q4 2025 revenue $120.5 million, down 3.4% sequentially; full-year 2025 revenue $500.6 million, down 10.9% year-over-year.
- Q4 Adjusted EBITDA $30.2 million, margin 25.1% (up 20 basis points sequentially); full-year Adjusted EBITDA $116.9 million, margin 23.4%.
- Retail first strategy: retail made up ~70.5% of Q4 revenue; retail sales $85.0 million in Q4, up 1.4% quarter-over-quarter.
- +12 more takeaways
Capricor Therapeutics Q4 2025 Earnings Call - BLA Accepted, PDUFA Aug 22 2026
Capricor walked into 2026 with the outcome every biotech CFO and patient advocate prays for. The FDA has accepted the companys Class 2 BLA resubmission for Deramiocel and set a PDUFA target action dat...
- FDA accepted Capricors Class 2 BLA resubmission for Deramiocel, PDUFA date set for August 22, 2026.
- HOPE-3 pivotal trial (n=106) met primary endpoint Performance of the Upper Limb and all Type I error controlled secondaries.
- Left ventricular ejection fraction showed a 91 percent slowing of disease progression overall, with a p value of 0.01 in the cardiomyopathy subgroup.
- +16 more takeaways
Silvaco Q4 FY2025 Earnings Call - FTCO AI traction and Mixel IP turbocharge bookings, targeting profitability
Silvaco closed Q4 FY2025 with a clear inflection: bookings and revenue landed near the top of guidance, driven by a faster-than-expected commercial ramp of FTCO, the companys AI-driven process develop...
- Q4 bookings were $18.3 million, at the high end of guidance; Q4 revenue was also $18.3 million, above guidance.
- TCAD delivered a large sequential rebound: bookings rose 70% to $9.2 million and revenue rose 34% to $8.7 million, driven by FTCO adoption.
- FTCO, Silvacos AI-driven process development platform, signed a second customer in Asia in Q4, and management says adoption is accelerating beyond memory use cases.
- +12 more takeaways
Atlanticus Holdings Corporation Fourth Quarter 2025 Earnings Call - Mercury Deal Doubles Balance Sheet, Integration Ahead of Plan
Atlanticus closed a transformational 2025 by completing the Mercury Financial acquisition, roughly doubling its balance sheet to about $7 billion and adding 1.3 million customers. Management says inte...
- Mercury acquisition completed in 2025, roughly doubling Atlanticus’s balance sheet to about $7 billion and adding more than 1.3 million customers.
- Management says Phase one of Mercury portfolio repositioning is complete and is performing better than modeled, with additional phases continuing through 2026.
- Atlanticus acquired a $165 million retail credit portfolio during the quarter, strengthening its second-look point-of-sale position.
- +15 more takeaways
Allogene Therapeutics Q4 2025 Earnings Call - Data-Driven Year Ahead, ALPHA3 MRD Readout in April and ALLO-329 PoC in June
Allogene enters 2026 with a tight, evidence-first playbook: an April interim MRD readout from ALPHA3 that could validate allogeneic CAR T as frontline consolidation in large B-cell lymphoma, and a Jun...
- April 2026: interim MRD futility analysis from ALPHA3 will report MRD clearance in 24 patients, 12 per arm, plus early safety; company has set an internal meaningful threshold at a 25% to 30% absolute delta in MRD conversion.
- June 2026: proof of concept readout expected for ALLO-329 in the phase 1 RESOLUTION trial, with translational and early clinical signals from dose level 1.
- ALLO-329 is engineered as a dual CD19/CD70 allogeneic CAR T with Dagger technology, designed to enable meaningful expansion and persistence at low, or possibly no, conventional lymphodepletion.
- +12 more takeaways